DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD. et al.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial.
Lancet Oncol 2018;
19: 497-509
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.